Team:LMU-Munich/Team/Collaborations

From 2014.igem.org

(Difference between revisions)
(Collaborations)
 
(23 intermediate revisions not shown)
Line 1: Line 1:
{{Template:Team:LMU-Munich/Playground/menu}}
{{Template:Team:LMU-Munich/Playground/menu}}
-
 
+
<html>
 +
<section>
 +
<section>
 +
<div class="text-width">
 +
</html>
= Collaborations =
= Collaborations =
Collaborations and the exchange of knowledge were important aspects during our iGEM participation. Therefore we had an intensive collaboration with the iGEM team Groningen (Netherlands) and laid a high priority on the exchange with the Rathenau Institute also located in the Netherlands. In addition we also took part in the Interlab Study of this year´s iGEM competition.
Collaborations and the exchange of knowledge were important aspects during our iGEM participation. Therefore we had an intensive collaboration with the iGEM team Groningen (Netherlands) and laid a high priority on the exchange with the Rathenau Institute also located in the Netherlands. In addition we also took part in the Interlab Study of this year´s iGEM competition.
 +
 +
<html>
 +
</div>
 +
</section>
 +
<section class="bg-color-2">
 +
<div>
 +
</html>
== Interlab Study ==
== Interlab Study ==
=== Background: ===
=== Background: ===
-
The aim of the Interlab study was to evaluate three devices consisting of different Anderson promoters fused to GFP in two different backbones: the high-copy plasmid [http://parts.igem.org/Part:pSB1C3 pSB1C3] (100-300 copies/cell) and the medium-copy plasmid [http://parts.igem.org/Part:pSB3K3 pSB3K3] (20-30 copies/cell). The devices were distributed by iGEM and the flourescence evaluation method was free of choice. For more details check: [https://2014.igem.org/Tracks/Measurement/Interlab_study Interlab Study@iGEM]
+
The aim of the Interlab study was to evaluate three devices consisting of different Anderson promoters fused to GFP in two different backbones: the high-copy plasmid [http://parts.igem.org/Part:pSB1C3 pSB1C3] (100-300 copies/cell) and the low-to-medium-copy plasmid [http://parts.igem.org/Part:pSB3K3 pSB3K3] (20-30 copies/cell). The devices were distributed by iGEM and the flourescence evaluation method was free of choice. For more details check: [https://2014.igem.org/Tracks/Measurement/Interlab_study Interlab Study@iGEM]
=== The devices: ===
=== The devices: ===
Line 22: Line 33:
=== Flow cytometry analysis: ===
=== Flow cytometry analysis: ===
-
For each measurement 50 µl of an overnight culture were first incubated with 1 µl of the membrane stain FM4-64 (final concentration: 4ng/µl) at 37°C for 60 minutes. This is necessary to differentiate between dust or cell particles and intact cells during the measurement. After the incubation, 1 µl of each sample was diluted in 200 µl phosphate buffered saline solution and then evaluated via flow cytometry. In order to generate meaningful results the described measurement were perfomed three times with technical replicates.  
+
For each measurement 50 µl of an overnight culture were first incubated with 1 µl of the membrane stain FM4-64 (final concentration: 4ng/µl) at 37°C for 60 minutes. This is necessary to differentiate between dust or cell particles and intact cells during the measurement. After the incubation, 1 µl of each sample was diluted in 200 µl phosphate buffered saline solution and then evaluated via flow cytometry. In order to generate meaningful results the described measurements were perfomed three times with technical replicates.  
For the analysis, all events were gated for a signal in the red channel (which corresponds to intact cells). For those events, the gfp-fluorescence was measured in fluorescence units. The graph below shows the avarage of the geometric mean of the gfp signals from 3 experiments. The empty DH5α strain was used as control for auto fluorescence of the cells.
For the analysis, all events were gated for a signal in the red channel (which corresponds to intact cells). For those events, the gfp-fluorescence was measured in fluorescence units. The graph below shows the avarage of the geometric mean of the gfp signals from 3 experiments. The empty DH5α strain was used as control for auto fluorescence of the cells.
Line 145: Line 156:
=== Outlook ===
=== Outlook ===
-
The LMU-iGEM team is looking forward to the presentation of iGEM HQ results, were we hope to see a mixture of different methods utilized - hopefully with similar outcomes.  We are curious how the absolute and relative results might differ; this might be a milestone towards ensuring reproducibility of scientific data produced by a huge number of different labs and methods.  
+
The LMU-iGEM team is looking forward to the presentation of iGEM HQ results, where we hope to see a mixture of different methods utilized - hopefully with similar outcomes.  We are curious how the absolute and relative results might differ; this might be a milestone towards ensuring reproducibility of scientific data produced by a huge number of different labs and methods.  
<br>
<br>
<br>
<br>
<br>
<br>
<br>
<br>
 +
 +
<html>
 +
</div>
 +
</section>
 +
<section class="bg-color-3">
 +
<div>
 +
</html>
== Collaboration with Team Groningen ==
== Collaboration with Team Groningen ==
 +
 +
[[File:Groningen_2014_logo.png|thumb|300px|right]]
 +
On August 1st, not only the collaboration with the Rathenau Instituut but also the cooperation with [https://2014.igem.org/Team:Groningen iGEM Team Groningen], was kicked off. During the first group chat with the Rathenau Institute, we were introduced to members of the iGEM Team Groningen that had with their 'Lacto Aid' a quite similar project idea to our BaKillus. As we pursue the same idea but work with different chassis, different targets and aim for different applications, we decided not to see them as rivals but rather use that chance to learn from their experiences and also support them, when help is required.
 +
From then on, we held regular Skype meetings and supported each other by exchanging views and thoughts about the feasibility and social desirability of our applications inspired by the guidelines of the Rathenau scenarios. Encouraged by this first steps, we also helped each other out in the lab.
 +
 +
=== Efforts of team Groningen===
 +
 +
As our BaKillus targets ''Staphylococcus aureus'', but we do not have access to S2 laboratories, and thus unfortunately cannot experiment with this bacterium. Our collaboration partner kindly provided us help by testing the subtilin producer ''Bacillus subtilis'' ATCC6633 in a spot-on-lawn assay on different ''S. aureus'' strains, including MRSA. Fortunately, the results could prove subtilin has inhibitory impact on ''S.aureus'' and thus, serves as excellent killing strategy for our project.
 +
 +
[[File:LMU14 killing subtilin MRSA.png|thumb|700px|center|Fig. 1. Spot-on-lawn assay with the subtilin producer on three different ''S. aureus'' lawns]]
 +
 +
The results are part of our killing subproject and can be seen [https://2014.igem.org/Team:LMU-Munich/Project/Bakillus here] or detailed information downloaded [[Media:LMU14_Groningen_Report_Munchen.pdf|here]].
=== Work done in our Lab ===
=== Work done in our Lab ===
On Monday 13th of October we received parts to be evaluated in ''Bacillus subtilis'' from the iGEM Team Groningen.
On Monday 13th of October we received parts to be evaluated in ''Bacillus subtilis'' from the iGEM Team Groningen.
-
The goal was to evaluate Promoters fused to a super-folded Green Fluorescent Protein (sfGFP)  towards their activity in ''B. subtilis''. In order to do so we had to bring the BioBricks into our integrative BioBrick compatible backbone pBS1C (LINK). The final analysis was done using fluorescent-activated cell sorting (FACS).
+
The goal was to evaluate Promoters fused to a super-folded Green Fluorescent Protein (sfGFP)  towards their activity in ''[https://2014.igem.org/Team:LMU-Munich/Project/B_subtilis B. subtilis]''. In order to do so we had to bring the BioBricks into our integrative BioBrick compatible backbone [http://parts.igem.org/Part:BBa_J179000 pSB1C]. The final analysis was done using fluorescent-activated cell sorting ([https://static.igem.org/mediawiki/2014/0/02/LMU_Munich14_FACS.pdf FACS]). The results of the strains carrying the Promoter-sfGFP insertion were compared to the ''[https://2014.igem.org/Team:LMU-Munich/Project/B_subtilis B. subtilis]'' W168 strain.
-
Results:
+
The following Promoters were analyzed:
 +
[http://parts.igem.org/Part:BBa_K1033219 CP1],
 +
[http://parts.igem.org/Part:BBa_K1033221 CP11],
 +
[http://parts.igem.org/Part:BBa_K1033222 CP29],
 +
[http://parts.igem.org/Part:BBa_K1033223 CP30],
 +
[http://parts.igem.org/Part:BBa_K1033224 CP41],
 +
[http://parts.igem.org/Part:BBa_K1033225 CP44]
 +
 
 +
The data achieved via FACS shows no change in distribution of FL1-A intensity. This strongly inidcates, that the promoter-''sfGFP'' constructs are not active when integrated into the ''[https://2014.igem.org/Team:LMU-Munich/Project/B_subtilis B. subtilis]'' chromosome. This might however be not only due to an lack of Promoter activity. To further invesitgate a quantitative assay using promoter-''lux'' fusions should be carried out.
 +
 
 +
<html>
 +
<div class="box-center">
 +
<ul class="bxgallery">
 +
    <li><img src="https://static.igem.org/mediawiki/2014/e/ee/LMU14_Collaboration_CP1.PNG" alt="CP1 (red, triplicates) and Wildtype (black, duplicates)"/></li>
 +
    <li><img src="https://static.igem.org/mediawiki/2014/a/ae/LMU14_Collaboration_CP11.PNG" alt="CP11 (red, triplicates) and Wildtype (black, duplicates)"/></li>
 +
    <li><img src="https://static.igem.org/mediawiki/2014/d/d3/LMU14_Collaboration_CP29.PNG" alt="CP29 (red, triplicates) and Wildtype (black, duplicates)"/></li>
 +
    <li><img src="https://static.igem.org/mediawiki/2014/4/42/LMU14_Collaboration_CP30.PNG" alt="CP30 (red, triplicates) and Wildtype (black, duplicates)"/></li>
 +
    <li><img src="https://static.igem.org/mediawiki/2014/6/64/LMU14_Collaboration_CP41.PNG" alt="CP41 (red, triplicates) and Wildtype (black, duplicates)"/></li>
 +
    <li><img src="https://static.igem.org/mediawiki/2014/e/e7/LMU14_Collaboration_CP44.PNG" alt="CP44 (red, triplicates) and Wildtype (black, duplicates)"/></li>
 +
</ul>
 +
</div>
 +
</html>
 +
 
 +
<i>Table 1: FACS Data</i>
 +
{| class="wikitable"
 +
|-
 +
!<b>Promoter</b>
 +
!<b>Count</b>
 +
!<b>Mean FL1-A</b>
 +
|-
 +
!rowspan="1"|<b>W168 (Wild type strain)</b>
 +
|627609
 +
|155.95
 +
|-
 +
!rowspan="1"|<b>W168 (Wild type strain)</b>
 +
|86172
 +
|186.03
 +
|-
 +
!rowspan="1"|<b>CP1</b>
 +
|679126
 +
|163.13
 +
|-
 +
!rowspan="1"|<b>CP1</b>
 +
|587189
 +
|160.54
 +
|-
 +
!rowspan="1"|<b>CP1</b>
 +
|644350
 +
|161.32
 +
|-
 +
!rowspan="1"|<b>CP11</b>
 +
|558153
 +
|164.57
 +
|-
 +
!rowspan="1"|<b>CP11</b>
 +
|371964
 +
|194.71
 +
|-
 +
!rowspan="1"|<b>CP11</b>
 +
|169210
 +
|188.28
 +
|-
 +
!rowspan="1"|<b>CP29</b>
 +
|50758
 +
|310.50
 +
|-
 +
!rowspan="1"|<b>CP29</b>
 +
|399988
 +
|173.85
 +
|-
 +
!rowspan="1"|<b>CP29</b>
 +
|464802
 +
|158.56
 +
|-
 +
!rowspan="1"|<b>CP30</b>
 +
|665875
 +
|155.95
 +
|-
 +
!rowspan="1"|<b>CP30</b>
 +
|657525
 +
|155.84
 +
|-
 +
!rowspan="1"|<b>CP30</b>
 +
|463322
 +
|157.94
 +
|-
 +
!rowspan="1"|<b>CP41</b>
 +
|463478
 +
|157.61
 +
|-
 +
!rowspan="1"|<b>CP41</b>
 +
|463578
 +
|157.95
 +
|-
 +
!rowspan="1"|<b>CP41</b>
 +
|463237
 +
|159.17
 +
|-
 +
!rowspan="1"|<b>CP44</b>
 +
|463306
 +
|158.39
 +
|-
 +
!rowspan="1"|<b>CP44</b>
 +
|463375
 +
|157.43
 +
|-
 +
!rowspan="1"|<b>CP44</b>
 +
|463508
 +
|157.34
 +
|-
 +
|}
 +
 
 +
<html>
 +
</div>
 +
</section>
 +
<section class="bg-color-1">
 +
<div>
 +
</html>
== A proposal of the German iGEM Teams concerning Intellectual Property ==
== A proposal of the German iGEM Teams concerning Intellectual Property ==
Line 200: Line 347:
References:
References:
*[http://www.nature.com/news/synthetic-biology-cultural-divide-1.15149| Bryn Nelson ‘Synthetic Biology: Cultural Divide ’, Nature 509, 152–154, 08 May 2014]
*[http://www.nature.com/news/synthetic-biology-cultural-divide-1.15149| Bryn Nelson ‘Synthetic Biology: Cultural Divide ’, Nature 509, 152–154, 08 May 2014]
 +
 +
<html>
 +
</div>
 +
</section>
 +
<section class="bg-color-2">
 +
<div>
 +
</html>
== Collaboration with Team Virginia ==
== Collaboration with Team Virginia ==
Line 236: Line 390:
-
 
+
<html>
 +
</div>
 +
</section>
 +
</section>
 +
</html>
{{Template:Team:LMU-Munich/Playground/footer}}
{{Template:Team:LMU-Munich/Playground/footer}}
<html><script>initiateNavigation("team");</script></html>
<html><script>initiateNavigation("team");</script></html>

Latest revision as of 03:23, 18 October 2014

Collaborations

Collaborations and the exchange of knowledge were important aspects during our iGEM participation. Therefore we had an intensive collaboration with the iGEM team Groningen (Netherlands) and laid a high priority on the exchange with the Rathenau Institute also located in the Netherlands. In addition we also took part in the Interlab Study of this year´s iGEM competition.

Interlab Study

Background:

The aim of the Interlab study was to evaluate three devices consisting of different Anderson promoters fused to GFP in two different backbones: the high-copy plasmid [http://parts.igem.org/Part:pSB1C3 pSB1C3] (100-300 copies/cell) and the low-to-medium-copy plasmid [http://parts.igem.org/Part:pSB3K3 pSB3K3] (20-30 copies/cell). The devices were distributed by iGEM and the flourescence evaluation method was free of choice. For more details check: Interlab Study@iGEM

The devices:

  • Device one: BBa_I20260 consisting of J23101-B0032-E0040-B0015 in the backbone pSB3K3
Status: ready for evaluation
  • Device two: BBa_J23101 + BBa_E0240, each in the backbone pSB1C3
Status: cloning before evaluation
  • Device three: BBa_J23115 + BBa_E0240, each in the backbone pSB1C3
Status: cloning before evaluation

The cloning:

Devices two and three were built from their individual parts. The plasmids containing the promotors (BBa_J23101 and BBa_J23115) were cut open with SpeI-HF and PstI-HF restriction enzymes. The XbaI and PstI-HF digested GFP (BBa_E0240) was then ligated downstream of the promotors. Both devices were transformed into DH5α, plated out on chloramphenicol [35mg/µl] LB-agar plates and tested via colony-PCR to identify positive clones. For verification PCR-positive clones were sequenced: device two and device three

Flow cytometry analysis:

For each measurement 50 µl of an overnight culture were first incubated with 1 µl of the membrane stain FM4-64 (final concentration: 4ng/µl) at 37°C for 60 minutes. This is necessary to differentiate between dust or cell particles and intact cells during the measurement. After the incubation, 1 µl of each sample was diluted in 200 µl phosphate buffered saline solution and then evaluated via flow cytometry. In order to generate meaningful results the described measurements were perfomed three times with technical replicates.

For the analysis, all events were gated for a signal in the red channel (which corresponds to intact cells). For those events, the gfp-fluorescence was measured in fluorescence units. The graph below shows the avarage of the geometric mean of the gfp signals from 3 experiments. The empty DH5α strain was used as control for auto fluorescence of the cells.

For details please check our Interlab study submission: LMU-Munich Interlab form

Results:



The results indicate that the promoter BBa_K823005 shows the highest expression of GFP, followed by the device BBa_I20260 (BBa_K823005 + B0032). The lowest GFP expression was measured with the device carrying BBa_K823012.

Discussion

The results generated here show a 10-fold higher expression read out with GFP for [http://parts.igem.org/Part:BBa_K823005 BBa_K823005] compared to [http://parts.igem.org/Part:BBa_K823012 BBa_K823012]. Having a closer look at the [http://parts.igem.org/Part:BBa_I20260 BBa_I20260] device, the utilization of the low to medium-copy plasmid [http://parts.igem.org/Part:pSB3K3 pSB3K3] explains the lower expression of GFP compared to [http://parts.igem.org/Part:BBa_K823005 BBa_K823005], despite containing the same insert.

Outlook

The LMU-iGEM team is looking forward to the presentation of iGEM HQ results, where we hope to see a mixture of different methods utilized - hopefully with similar outcomes. We are curious how the absolute and relative results might differ; this might be a milestone towards ensuring reproducibility of scientific data produced by a huge number of different labs and methods.



Collaboration with Team Groningen

Groningen 2014 logo.png

On August 1st, not only the collaboration with the Rathenau Instituut but also the cooperation with iGEM Team Groningen, was kicked off. During the first group chat with the Rathenau Institute, we were introduced to members of the iGEM Team Groningen that had with their 'Lacto Aid' a quite similar project idea to our BaKillus. As we pursue the same idea but work with different chassis, different targets and aim for different applications, we decided not to see them as rivals but rather use that chance to learn from their experiences and also support them, when help is required. From then on, we held regular Skype meetings and supported each other by exchanging views and thoughts about the feasibility and social desirability of our applications inspired by the guidelines of the Rathenau scenarios. Encouraged by this first steps, we also helped each other out in the lab.

Efforts of team Groningen

As our BaKillus targets Staphylococcus aureus, but we do not have access to S2 laboratories, and thus unfortunately cannot experiment with this bacterium. Our collaboration partner kindly provided us help by testing the subtilin producer Bacillus subtilis ATCC6633 in a spot-on-lawn assay on different S. aureus strains, including MRSA. Fortunately, the results could prove subtilin has inhibitory impact on S.aureus and thus, serves as excellent killing strategy for our project.

Fig. 1. Spot-on-lawn assay with the subtilin producer on three different S. aureus lawns

The results are part of our killing subproject and can be seen here or detailed information downloaded here.

Work done in our Lab

On Monday 13th of October we received parts to be evaluated in Bacillus subtilis from the iGEM Team Groningen. The goal was to evaluate Promoters fused to a super-folded Green Fluorescent Protein (sfGFP) towards their activity in B. subtilis. In order to do so we had to bring the BioBricks into our integrative BioBrick compatible backbone [http://parts.igem.org/Part:BBa_J179000 pSB1C]. The final analysis was done using fluorescent-activated cell sorting (FACS). The results of the strains carrying the Promoter-sfGFP insertion were compared to the B. subtilis W168 strain.

The following Promoters were analyzed: [http://parts.igem.org/Part:BBa_K1033219 CP1], [http://parts.igem.org/Part:BBa_K1033221 CP11], [http://parts.igem.org/Part:BBa_K1033222 CP29], [http://parts.igem.org/Part:BBa_K1033223 CP30], [http://parts.igem.org/Part:BBa_K1033224 CP41], [http://parts.igem.org/Part:BBa_K1033225 CP44]

The data achieved via FACS shows no change in distribution of FL1-A intensity. This strongly inidcates, that the promoter-sfGFP constructs are not active when integrated into the B. subtilis chromosome. This might however be not only due to an lack of Promoter activity. To further invesitgate a quantitative assay using promoter-lux fusions should be carried out.

  • CP1 (red, triplicates) and Wildtype (black, duplicates)
  • CP11 (red, triplicates) and Wildtype (black, duplicates)
  • CP29 (red, triplicates) and Wildtype (black, duplicates)
  • CP30 (red, triplicates) and Wildtype (black, duplicates)
  • CP41 (red, triplicates) and Wildtype (black, duplicates)
  • CP44 (red, triplicates) and Wildtype (black, duplicates)

Table 1: FACS Data

Promoter Count Mean FL1-A
W168 (Wild type strain) 627609 155.95
W168 (Wild type strain) 86172 186.03
CP1 679126 163.13
CP1 587189 160.54
CP1 644350 161.32
CP11 558153 164.57
CP11 371964 194.71
CP11 169210 188.28
CP29 50758 310.50
CP29 399988 173.85
CP29 464802 158.56
CP30 665875 155.95
CP30 657525 155.84
CP30 463322 157.94
CP41 463478 157.61
CP41 463578 157.95
CP41 463237 159.17
CP44 463306 158.39
CP44 463375 157.43
CP44 463508 157.34

A proposal of the German iGEM Teams concerning Intellectual Property

During the meetup of the German iGEM teams from 23rd to 25th May a workshop also took place in which amongst others we discussed the topic of bioethics. Moral questions were addressed, regarding the value of life and human influence on it, as well as questions dealing with the possible socioeconomic effects of synthetic biology.

Especially the topic of an open source vs. patent controlled field accounted for a large part of the discussion. During the discussion one student brought up the point that the legal status of parts in the parts registry remains unclear and that there are parts (e.g. [http://parts.igem.org/Part:BBa_K180009 BBa_K180009]) where it only becomes clear upon a closer that the rights are company–owned. This issue (that the legal status of parts in the registry remains uncertain) is also mentioned in a recent article published by Nature [1]:

"[N]o one can say with any certainty how many of these parts are themselves entirely free of patent claims."

We, the German iGEM teams, therefore like to suggest the addition of a new feature to the parts registry:

A dedicated data field of license information for each BioBrick part.

For the implementation, we propose to introduce two new fields to the BioBrick part entries in the registry:

  1. A string property "LicenseInfo"
  2. A traffic light property (grey, green, yellow, red) to indicate the level of legal protection (unknown, BPA-like, free for research purposes, heavily protected)


TU-BS Part licence info.png


Implementing this feature would in our opinion further clarify and extend the parts info, provide a machine-readable format and thus improve future entries. With the emerging Entrepreneurship track and applications getting closer to industrial realization, the legal status becomes more and more relevant. It would also raise awareness to the topic of the legal status of parts. This could lead to a debate which could further promote the idea of open source, ideally. At the same time we hope that the examination of most parts will show that they are indeed free of restrictive legal protections.

The German iGEM Teams,

Aachen Berlin Bielefeld-CeBiTec Braunschweig Freiburg Goettingen Hannover Heidelberg LMU-Munich Marburg Saarland Tuebingen TU Darmstadt

References:

  • [http://www.nature.com/news/synthetic-biology-cultural-divide-1.15149| Bryn Nelson ‘Synthetic Biology: Cultural Divide ’, Nature 509, 152–154, 08 May 2014]

Collaboration with Team Virginia

   
    
        
    
     
    
        
The global synthetic biology awareness and acceptance survey designed by the Virginia iGEM-team was a great opportunity to generate a lot of data,
since more than 40 teams participated!


Hi there!

Welcome to our Wiki! I'm BaKillus, the pathogen-hunting microbe, and I'll guide you on this tour through our project. If you want to learn more about a specific step, you can simply close the tour and come back to it anytime you like. So let's start!

What's the problem?

First of all, what am I doing here? The problem is, pathogenic bacteria all around the world are becoming more and more resistant against antimicrobial drugs. One major reason for the trend is the inappropriate use of drugs. With my BaKillus super powers, I want to reduce this misuse and thus do my part to save global health.

Sensing of pathogens

To combat the pathogenic bacteria, I simply eavesdrop on their communication. Bacteria talk with each other via quorum sensing systems, which I use to detect them and trigger my responses.

Adhesion

The more specific and effective I can use my powers, the lower the danger is of provoking new resistance development. So I catch pathogens whenever I get hold of them and stick to them until my work is done.

Killing

Talking about my work - killing pathogens is finally what I am made for. In response to quorum sensing molecules of the pathogens, I export a range of antimicrobial substances leading to dissipation of biofilms and the killing of the targeted bacteria.

Suicide switch

When the job is done and all the bad guys are finished, you don't need a super hero anymore. So after fulfilling my work I say goodbye to the world by activating my suicide switch.

Application

Of course I'm not only a fictional hero, but a very real one. In two different prototypes, I could be used for diagnosis or treatment of pathogen-caused diseases. However, there is still a whole lot of regulational and economical questions that have to be answered before.

See you!

So now you know my short story - and it is time for me to return to my fight for a safer world. Feel free to take a closer look on my super powers, the process of my development or the plans for a medical application.